RNS Number : 7591D BSF Enterprise PLC 23 June 2023 23 June 2023 BSF Enterprise PLC ("BSF" or the "Company") Cultivated Meat Approved for Consumption in US BSF (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech company and owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is pleased to announce that cultivated meat has been approved for sale in the USA. As the US is one of the world's biggest consumers of meat, with approximately 40 billion kilograms consumed each year, this represents a significant step forward for the cultivated meat industry. Two cultivated meat companies, UPSIDE Foods, Inc. ("UPSIDE Foods") and Eat JUST, have been granted regulatory approval from the joint USDA and FDA framework to sell their cultivated chicken products to US consumers. UPSIDE Foods plans to produce up to 22,000 kilograms of cultivated meat a year in the near-term with work having started on a larger operation with annual capacity of millions of pounds of cultivated meat products. Eat JUST intends to sell its products through a chain of restaurants through the US with the first to be opened shortly in Washington DC. As one of the biggest markets in the world, with some of the most exacting standards for food safety, this development in the USA substantially validates cultivated meat as a viable and safe alternative to conventional meat. This paves the way for other countries to follow suit, other companies within the industry to receive approval, and ultimately full commercialisation of cultivated meat. Che Connon, CEO of 3D Bio Tissues, said: "This announcement marks a monumental milestone in the development of the Cultivated Meat industry. The US Government approval provides access to both UPSIDE Foods' and Eat Just's sustainable and ethical meat products in a country that is one of the world's biggest meat consumers. "US regulations for food safety are some of the most stringent in the world. Today's approval will pave the way for the Government approval for other producers of cultivated meat in the US, including companies that 3D Bio Tissues is looking to partner with and provide our patented serum-free and animal-free cell booster City-MixTM to help scale up cultivated meat production. " This decision has the potential to rapidly accelerate the development of the Cultivated Meat market in America and provides a clear framework for other countries to also follow." -EndsFor further enquiries, please visit www.bsfenterprise.com or contact: Via SEC Newgate below BSF Enterprise PLC Che Connon - CEO & Executive Director Geoff Baker - Executive Director Shard Capital (Broker) Damon Heath Isabella Pierre SEC Newgate Communications) Bob Huxford 0203 971 7000 (Financial 020 3757 6882 Elisabeth Cowell George Esmond BSF@secnewgate.co.uk ISIN of the Ordinary Shares is GB00BHNBDQ51 SEDOL Code is BHNBDQ5. Notes to Editors BSF Enterprise PLC (BSF) is focused on unlocking the next generation of biotechnological solutions - using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes, as part of a radical transformation to deliver sustainable solutions across a variety of sectors. It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with patent-protected IP that is already producing human corneas to help restore vision to millions of people. Building on this success, it aims to produce the UK's first high quality lab-grown meat from its laboratory in Newcastle the next 12 months, transforming the meat-production industry towards an ethical and sustainable practice. BSF aims to deliver growth to shareholders through the continued commercialisation of 3DBT's IP, which has multiple applications, as well as acquiring complementary businesses. It aims to acquire a suite of technologies that underpins the development of tissue templating for corneas, meat and leather, and license out the IP to manufacturers, wholesalers and distributors to help manufacture the products at scale. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRAFLFFIRIIVFIV